Cuorips: Interim report
Cuorips: Internal Control Report - 8th Term (April 1, 2023 - March 31, 2024)
Cuorips: Confirmatory letter.
Cuorips: Securities Report - 8th term (April 1, 2023 to March 31, 2024)
Cuorips: Matters related to business plans and growth potential.
Cuorips: Announcements of individual stocks regarding the establishment of a subsidiary in USA.
Cuorips: Corporate Governance Report June 26, 2024
Cuorips: Announcements of individual stocks: Change of application period using long-term data in clinical trials of iPS-derived myocardial cell sheets.
Cuorips: Part of the Correction Notice for the 8th Regular General Meeting of Shareholders Invitation
Cuorips: Independent Company Executives Declaration
Cuorips: Change report.
Cuorips: Notice of Convening the Regular Shareholders' Meeting in 2024 and Other Electronic Provision Measures (Omitted Matters in Written Form)
Cuorips: Notice of Convening Regular Shareholders' Meeting for the Year 2024.
Cuorips: Notice of provision of cardiomyocyte sheets for treatment of dilated heart disease using human iPS cell-derived cardiomyocyte sheets
Cuorips: About some reports about our company
Cuorips: Announcement of the launch of a cell mass manufacturing value chain consortium that enables the development and practical application of next-generation regenerative medicine modalities
Cuorips: Notice regarding changes in officers
Cuorips: Notice regarding differences between individual results and previous fiscal year results
Cuorips: Summary of Financial Results for the Fiscal Year Ending March 31, 2024 [Japanese GAAP] (Consolidated)
Cuorips: Notice of commencement of joint development related to a cell mass manufacturing system based at Nakanoshima Qross
No Data